Burger - Figure 36
Non-urachal Adenocarcinoma
FIG. 36: Neoadjuvant chemotherapy has been suggested as an integral part of the treatment of small cell carcinoma, based on the results of a small Phase 2 trial in 30 patients, 18 with non-metastatic and 12 with metastatic disease, treated with or without chemotherapy comprising ifosfamide, doxorubicin, etoposide, and cisplatin.[21] Downstaging was achieved in 78% of cases, and median overall survival was not too bad, being 58 months in the non-metastatic cases and 13 months in the patients with metastatic disease. This supports the contention that neoadjuvant chemotherapy is the optimal strategy.
References
Siefker-Radtke AO, Kamat AM, Grossman HB, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009;27:2592−7 https://doi.org/10.1200/JCO.2008.19.0256
